FinTrust Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-1,235
Closed -$40.5K – 1274
2023
Q4
$40.5K Hold
1,235
– – 0.01% 544
2023
Q3
$34.4K Hold
1,235
– – 0.01% 541
2023
Q2
$34.9K Hold
1,235
– – 0.01% 512
2023
Q1
$34.9K Hold
1,235
– – 0.01% 511
2022
Q4
$34.9K Hold
1,235
– – 0.01% 510
2022
Q3
$40K Hold
1,235
– – 0.01% 550
2022
Q2
$45K Hold
1,235
– – 0.01% 547
2022
Q1
$57K Hold
1,235
– – 0.01% 534
2021
Q4
$76K Sell
1,235
-93
-7% -$6.43K 0.02% 479
2021
Q3
$99K Hold
1,328
– – 0.03% 417
2021
Q2
$123K Buy
1,328
+1,235
+1,328% +$105K 0.03% 371
2021
Q1
$8K Hold
93
– – ﹤0.01% 938
2020
Q4
$9K Hold
93
– – ﹤0.01% 857
2020
Q3
$6K Buy
+93
New +$5.45K ﹤0.01% 919
2019
Q1
– Sell
-2,390
Closed -$57K – 1250
2018
Q4
$57K Buy
+2,390
New +$67.3K 0.03% 354

Other funds holding ARKG

FinTrust Capital Advisors's ARKG Position: Q1 2024 in Review

FinTrust Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2024, closing a stake of 1,235 shares — an estimated $40.5K sold.

FinTrust Capital Advisors first reported a position in ARKG in Q4 2018 and held it in 15 quarters. The position peaked at $123K in Q2 2021. 286 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

  • FinTrust Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2024 after selling out during the quarter.
  • FinTrust Capital Advisors sold 1,235 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $40.5K.
  • FinTrust Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2018 and held it in 15 quarters.
  • FinTrust Capital Advisors's ARK Genomic Revolution ETF position peaked at $123K in Q2 2021.
  • 286 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on FinTrust Capital Advisors's 13F filing for Q1 2024, filed 2 May 2024.